Driehaus Capital Management’s Alder Biopharmaceuticals ALDR Stock Holding History

Driehaus Capital Management’s Portfolio ALDR Stock Details ALDR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-232,874	Closed	-$7.63M	–	700
2016 Q3	$7.63M	Buy	232,874 +79,431	+52%	+$2.42M	0.26%	83
2016 Q2	$3.83M	Buy	+153,443	New	+$4.15M	0.14%	161
2015 Q4	–	Sell	-66,716	Closed	-$2.19M	–	677
2015 Q3	$2.19M	Sell	66,716 -14,691	-18%	-$625K	0.08%	270
2015 Q2	$4.31M	Sell	81,407 -16,019	-16%	-$583K	0.15%	167
2015 Q1	$2.81M	Sell	97,426 -1,404	-1%	-$38.5K	0.1%	262
2014 Q4	$2.88M	Buy	98,830 +3,108	+3%	+$55.8K	0.12%	235
2014 Q3	$1.21M	Sell	95,722 -2,087	-2%	-$31.5K	0.05%	405
2014 Q2	$1.96M	Buy	+97,809	New	+$1.38M	0.06%	349

Other funds holding ALDR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

FCMI

Foresite Capital Management III Larkspur, California $37.9M AUM 6.87% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return

Driehaus Capital Management's ALDR Position: Q4 2016 in Review

Driehaus Capital Management sold out of Alder Biopharmaceuticals (ALDR) in Q4 2016, closing a stake of 232,874 shares — an estimated $7.63M sold.

Driehaus Capital Management first reported a position in ALDR in Q2 2014 and held it in 8 quarters. The position peaked at $7.63M in Q3 2016. 145 funds tracked by Wall St. Rank hold ALDR as of Q4 2016.

Driehaus Capital Management reported no remaining Alder Biopharmaceuticals position as of Q4 2016 after selling out during the quarter.
Driehaus Capital Management sold 232,874 Alder Biopharmaceuticals shares in Q4 2016, an estimated $7.63M.
Driehaus Capital Management first reported a position in Alder Biopharmaceuticals in Q2 2014 and held it in 8 quarters.
Driehaus Capital Management's Alder Biopharmaceuticals position peaked at $7.63M in Q3 2016.
145 funds tracked by Wall St. Rank held Alder Biopharmaceuticals as of Q4 2016.

Based on Driehaus Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.